Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway
暂无分享,去创建一个
K. Tohyama | T. Nakahara | A. Kitanaka | Y. Arao | T. Tsujioka | Shin-ichiro Suemori | Jun-ichiro Kida | Kanae Sakakibara | Nami Kurozumi | Takayuki Tsujioka